DK3687999T3 - Rapamycinderivater - Google Patents

Rapamycinderivater Download PDF

Info

Publication number: DK3687999T3
Authority: DK; Denmark
Prior art keywords: rapamycin derivatives; rapamycin; derivatives
Prior art date: 2017-09-26

Application number

DK18786408.7T

Other languages

English (en)

Inventor

Simone Bonazzi

Michael Connolly

David Jonathan Glass

Manuel Mihalic

Andrew William Patterson

Silvio Roggo

Tea Shavlakadze

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-26

Filing date

2018-09-25

Publication date

2024-02-12

2018-09-25 Application filed by Novartis Ag filed Critical Novartis Ag

2024-02-12 Application granted granted Critical

2024-02-12 Publication of DK3687999T3 publication Critical patent/DK3687999T3/da

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Obesity (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Psychology (AREA)

DK18786408.7T 2017-09-26 2018-09-25 Rapamycinderivater DK3687999T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762563312P	2017-09-26	2017-09-26
PCT/IB2018/057422 WO2019064182A1 (en)	2017-09-26	2018-09-25	RAPAMYCIN DERIVATIVES

Publications (1)

Publication Number	Publication Date
DK3687999T3 true DK3687999T3 (da)	2024-02-12

Family

ID=63857991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18786408.7T DK3687999T3 (da)	2017-09-26	2018-09-25	Rapamycinderivater

Country Status (23)

Country	Link
US (3)	US10800793B2 (da)
EP (2)	EP4365179A3 (da)
JP (2)	JP7387590B2 (da)
KR (2)	KR102794731B1 (da)
CN (2)	CN117417351A (da)
AR (1)	AR112834A1 (da)
AU (1)	AU2018342784B2 (da)
BR (1)	BR112020005898A2 (da)
CA (1)	CA3078191A1 (da)
DK (1)	DK3687999T3 (da)
ES (1)	ES2973975T3 (da)
FI (1)	FI3687999T3 (da)
HR (1)	HRP20240199T8 (da)
HU (1)	HUE065692T2 (da)
LT (1)	LT3687999T (da)
MX (2)	MX2020007265A (da)
PL (1)	PL3687999T3 (da)
PT (1)	PT3687999T (da)
RS (1)	RS65270B1 (da)
SI (1)	SI3687999T1 (da)
TW (1)	TW201920189A (da)
UY (1)	UY37900A (da)
WO (1)	WO2019064182A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11066416B2 (en)	2016-02-04	2021-07-20	The Johns Hopkins University	Rapafucin derivative compounds and methods of use thereof
AU2017213630B2 (en)	2016-02-04	2022-05-12	The Johns Hopkins University	Rapaglutins, novel inhibitors of GLUT and use thereof
EP3782636B1 (en)	2016-02-04	2024-05-15	The Johns Hopkins University	Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
UY37900A (es)	2017-09-26	2019-04-30	Novartis Ag	Nuevos derivados de rapamicina
MX2020011565A (es)	2018-05-01	2021-01-29	Revolution Medicines Inc	Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
EP3788050B1 (en)	2018-05-01	2024-08-28	Revolution Medicines, Inc.	C26-linked rapamycin analogs as mtor inhibitors
PT3813946T (pt)	2018-06-15	2024-07-10	Janssen Pharmaceutica Nv	Análogos da rapamicina e suas utilizações
DK3898637T3 (da)	2018-12-18	2025-02-17	Novartis Ag	Rapamycin-derivater
GB2586427B (en)	2019-01-22	2022-02-09	Aeovian Pharmaceuticals Inc	MTORC modulators and uses thereof
KR102497821B1 (ko) *	2019-08-23	2023-02-08	이화여자대학교 산학협력단	신규 mTOR 억제제 화합물 및 이의 용도
KR102486721B1 (ko) *	2019-08-23	2023-01-10	이화여자대학교 산학협력단	신규 mTOR 억제제 화합물 및 이의 용도
TW202126323A (zh) *	2019-10-01	2021-07-16	約翰斯赫普金斯大學	雷帕弗辛（Ｒａｐａｆｕｃｉｎ）衍生化合物及其使用方法
JP2023506410A (ja)	2019-12-05	2023-02-16	アナクリアセラピューティクス，インコーポレイテッド	ラパマイシン類似体及びその使用
EP4118431A1 (de)	2020-03-12	2023-01-18	Heinrich-Heine-Universität Düsseldorf	Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms
DE102020203224A1 (de)	2020-03-12	2021-09-16	Heinrich-Heine-Universität Düsseldorf	Inhibition von FKBP1A zur Therapie des Triple-negativen Mammakarzinoms
KR20250065937A (ko) *	2020-03-27	2025-05-13	에오비안 파마슈티컬스, 인크.	Mtorc1 조절제 및 이의 용도
TW202206093A (zh) *	2020-08-12	2022-02-16	中國醫藥大學	Ｓｅｍａ３ｄ拮抗劑用於預防或治療神經退化性疾病以及延長壽命之用途
CN119604293A (zh)	2022-05-25	2025-03-11	锐新医药公司	用mTOR抑制剂治疗癌症的方法
US20240360153A1 (en) *	2023-04-07	2024-10-31	Regeneron Pharmaceuticals, Inc.	Selective rapamycin analogs and uses thereof
WO2024243449A1 (en) *	2023-05-23	2024-11-28	Tornado Therapeutics, Inc.	Rapamycin derivatives and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4316885A (en)	1980-08-25	1982-02-23	Ayerst, Mckenna And Harrison, Inc.	Acyl derivatives of rapamycin
US4650803A (en)	1985-12-06	1987-03-17	University Of Kansas	Prodrugs of rapamycin
US5120842A (en)	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5151413A (en)	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5302584A (en)	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5527907A (en)	1993-11-19	1996-06-18	Abbott Laboratories	Macrolide immunomodulators
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
WO1996041865A1 (en)	1995-06-07	1996-12-27	Ariad Gene Therapeutics, Inc.	Rapamcycin-based regulation of biological events
JP2002514893A (ja)	1995-06-07	2002-05-21	アリアド・ジーン・セラピューティクス・インコーポレイテッド	生物学的事象のラパマイシンに基づく調節
AU712193B2 (en) *	1995-06-09	1999-10-28	Novartis Ag	Rapamycin derivatives
GB9606452D0 (en)	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
CA2257803C (en)	1996-07-12	2008-12-02	Ariad Pharmaceuticals, Inc.	Non immunosuppressive antifungal rapalogs
AU755784B2 (en)	1998-01-15	2002-12-19	Ariad Pharmaceuticals, Inc.	Regulation of biological events using multimeric chimeric proteins
ATE264863T1 (de)	1999-08-24	2004-05-15	Ariad Gene Therapeutics Inc	28-epirapaloge
CN104274442A (zh)	2001-02-19	2015-01-14	诺华股份有限公司	癌症的治疗
CA2472341C (en)	2002-02-01	2011-06-21	Ariad Gene Therapeutics, Inc.	Phosphorus-containing compounds & uses thereof
GB0504994D0 (en) *	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
GB0601406D0 (en)	2006-01-24	2006-03-08	Novartis Ag	Organic Compounds
US20090023768A1 (en) *	2006-02-24	2009-01-22	Novartis Ag	Rapamycin derivatives for treating neuroblastoma
WO2008022256A2 (en)	2006-08-16	2008-02-21	Blagosklonny Mikhail V	Methods and compositions for preventing or treating age-related diseases
GB0911888D0 (en) *	2009-07-08	2009-08-19	Oxford Biodynamics Ltd	Method of treating age related disorders
US20150361120A1 (en) *	2010-03-31	2015-12-17	Chengzhi Zhang	MACROLIDE INHIBITORS OF mTOR
US8906374B2 (en)	2010-04-20	2014-12-09	Cedars-Sinai Medical Center	Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
ES2635591T3 (es)	2011-02-04	2017-10-04	Synthon Bv	Procedimiento de fabricación de everolimus
EP2675450B1 (en)	2011-02-16	2016-02-10	Novartis AG	Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
EP2793893A4 (en)	2011-11-23	2015-07-08	Intellikine Llc	IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3109250A1 (en)	2015-06-23	2016-12-28	Synbias Pharma AG	Method for the synthesis of rapamycin derivatives
US10683308B2 (en) *	2015-09-11	2020-06-16	Navitor Pharmaceuticals, Inc.	Rapamycin analogs and uses thereof
EP3619216A1 (en)	2017-05-02	2020-03-11	Revolution Medicines, Inc.	Rapamycin analogs as mtor inhibitors
UY37900A (es)	2017-09-26	2019-04-30	Novartis Ag	Nuevos derivados de rapamicina
DK3898637T3 (da)	2018-12-18	2025-02-17	Novartis Ag	Rapamycin-derivater
HUE067396T2 (hu)	2019-03-26	2024-10-28	Novartis Ag	Izotiazolidin 1,1-dioxidot és 1,4-bután szultont tartalmazó rapamicinszármazékok és alkalmazásaik

2018
- 2018-09-24 UY UY0001037900A patent/UY37900A/es not_active Application Discontinuation
- 2018-09-24 AR ARP180102741A patent/AR112834A1/es unknown
- 2018-09-25 EP EP24150040.4A patent/EP4365179A3/en active Pending
- 2018-09-25 HU HUE18786408A patent/HUE065692T2/hu unknown
- 2018-09-25 CN CN202311329093.8A patent/CN117417351A/zh active Pending
- 2018-09-25 EP EP18786408.7A patent/EP3687999B1/en active Active
- 2018-09-25 WO PCT/IB2018/057422 patent/WO2019064182A1/en active Application Filing
- 2018-09-25 BR BR112020005898-0A patent/BR112020005898A2/pt unknown
- 2018-09-25 FI FIEP18786408.7T patent/FI3687999T3/fi active
- 2018-09-25 SI SI201831063T patent/SI3687999T1/sl unknown
- 2018-09-25 KR KR1020207007749A patent/KR102794731B1/ko active Active
- 2018-09-25 CA CA3078191A patent/CA3078191A1/en active Pending
- 2018-09-25 HR HRP20240199TT patent/HRP20240199T8/hr unknown
- 2018-09-25 RS RS20240184A patent/RS65270B1/sr unknown
- 2018-09-25 TW TW107133541A patent/TW201920189A/zh unknown
- 2018-09-25 PL PL18786408.7T patent/PL3687999T3/pl unknown
- 2018-09-25 JP JP2020516599A patent/JP7387590B2/ja active Active
- 2018-09-25 AU AU2018342784A patent/AU2018342784B2/en active Active
- 2018-09-25 US US16/141,856 patent/US10800793B2/en active Active
- 2018-09-25 MX MX2020007265A patent/MX2020007265A/es unknown
- 2018-09-25 KR KR1020257011373A patent/KR20250054121A/ko active Pending
- 2018-09-25 LT LTEPPCT/IB2018/057422T patent/LT3687999T/lt unknown
- 2018-09-25 PT PT187864087T patent/PT3687999T/pt unknown
- 2018-09-25 CN CN201880057805.6A patent/CN111094299B/zh active Active
- 2018-09-25 ES ES18786408T patent/ES2973975T3/es active Active
- 2018-09-25 DK DK18786408.7T patent/DK3687999T3/da active
2020
- 2020-07-13 MX MX2023001876A patent/MX2023001876A/es unknown
- 2020-08-27 US US17/004,434 patent/US20200392159A1/en not_active Abandoned
2021
- 2021-10-12 US US17/499,433 patent/US12091424B2/en active Active
2023
- 2023-05-18 JP JP2023081938A patent/JP7699626B2/ja active Active

Also Published As

Publication number	Publication date
JP7699626B2 (ja)	2025-06-27
KR102794731B1 (ko)	2025-04-14
US20220242878A1 (en)	2022-08-04
AU2018342784A1 (en)	2020-02-06
KR20250054121A (ko)	2025-04-22
HRP20240199T8 (hr)	2024-09-27
BR112020005898A2 (pt)	2020-11-17
AU2018342784B2 (en)	2021-01-28
UY37900A (es)	2019-04-30
HUE065692T2 (hu)	2024-06-28
PT3687999T (pt)	2024-02-12
KR20200059219A (ko)	2020-05-28
AR112834A1 (es)	2019-12-18
JP2023106500A (ja)	2023-08-01
EP3687999A1 (en)	2020-08-05
US12091424B2 (en)	2024-09-17
RS65270B1 (sr)	2024-03-29
EP3687999B1 (en)	2024-01-03
SI3687999T1 (sl)	2024-03-29
PL3687999T3 (pl)	2024-05-06
US10800793B2 (en)	2020-10-13
CN111094299A (zh)	2020-05-01
WO2019064182A1 (en)	2019-04-04
EP4365179A3 (en)	2024-07-10
RU2020112056A3 (da)	2022-02-18
FI3687999T3 (fi)	2024-02-14
CN111094299B (zh)	2023-10-31
RU2020112056A (ru)	2021-10-28
TW201920189A (zh)	2019-06-01
HRP20240199T1 (hr)	2024-04-26
US20190092788A1 (en)	2019-03-28
CA3078191A1 (en)	2019-04-04
ES2973975T3 (es)	2024-06-25
MX2023001876A (es)	2023-03-10
JP2020535134A (ja)	2020-12-03
LT3687999T (lt)	2024-02-26
CN117417351A (zh)	2024-01-19
JP7387590B2 (ja)	2023-11-28
MX2020007265A (es)	2020-09-18
EP4365179A2 (en)	2024-05-08
US20200392159A1 (en)	2020-12-17

Publication	Publication Date	Title
DK3687999T3 (da)	2024-02-12	Rapamycinderivater
EP3615539A4 (en)	2020-08-19	2-AMINO-QUINOLEINE DERIVATIVES
DK3319956T3 (da)	2021-03-29	Substituerede oxopyridinderivater
DK3642202T3 (da)	2023-01-30	Dihydro-pyrrolo-pyridin-derivater
DE202018003363U8 (de)	2019-01-24	Handgelenkssphygmomanometer
DK3615527T3 (da)	2024-05-06	Nye azaquinolin-derivater
CL2018000524S1 (es)	2018-10-05	Golilla
LT3830085T (lt)	2024-02-12	Deuterinti lanifibranoro dariniai
EP3546462A4 (en)	2020-07-01	NEW OXOISOQUINOLINE DERIVATIVE
DK3351526T3 (da)	2021-02-08	Diisopentylterephthalat
LT3402792T (lt)	2021-12-10	Chinolin-2-ono dariniai
DK3898637T3 (da)	2025-02-17	Rapamycin-derivater
LT3371168T (lt)	2020-10-12	Indolin-2-ono dariniai
DK3768669T3 (da)	2023-04-24	Piperazinazaspiroderivater
DK3679038T3 (da)	2024-05-27	Substituerede imidazoquinoliner
LT3680243T (lt)	2021-11-25	Pentaciklinis junginys
DK3652176T3 (da)	2022-01-17	Substituerede xanthinderivater
FI11939U1 (fi)	2018-01-22	Teline
PT3796975T (pt)	2023-11-15	Derivados de sulfonilaminobenzamida
DK3645513T3 (da)	2022-11-14	Benzazepinderivater
EP3590944A4 (en)	2020-12-09	AZETIDINE DERIVATIVE
EP3444345C0 (en)	2024-07-10	MICRO-143 RNA DERIVATIVE
EP3205308C0 (en)	2025-04-02	ENDOPROSTHESIS
EP3595647A4 (en)	2020-10-07	ARYL-PIPERIDINE DERIVATIVES
EP3782983A4 (en)	2022-01-26	ISOINDOLE DERIVATIVE